TY - JOUR
T1 - Advanced Age Is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy
AU - Nielsen, Matthew E.
AU - Shariat, Shahrokh F.
AU - Karakiewicz, Pierre I.
AU - Lotan, Yair
AU - Rogers, Craig G.
AU - Amiel, Gilad E.
AU - Bastian, Patrick J.
AU - Vazina, Amnon
AU - Gupta, Amit
AU - Lerner, Seth P.
AU - Sagalowsky, Arthur I
AU - Schoenberg, Mark P.
AU - Palapattu, Ganesh S.
N1 - Funding Information:
Shahrokh F. Shariat is supported by the Austrian Program for Advanced Research and Technology.
PY - 2007/3
Y1 - 2007/3
N2 - Objective: Bladder cancer (BCa) is a disease of older persons, the incidence of which is expected to increase as the population ages. There is controversy, however, regarding the outcomes of radical cystectomy (RC), the gold standard treatment of high-risk BCa, in patients of advanced chronological age. The aim of our study was to assess the impact of patient age on pathological characteristics and recurrence-free and disease-specific survival following RC. Methods: The records of 888 consecutive patients who underwent RC for transitional cell carcinoma (TCC) were reviewed. Age at RC was analyzed both as a continuous (yr) and categorical (≤60 yr old, n = 240; 60.1-70 yr old, n = 331; 70.1-80 yr old, n = 266; >80 yr old, n = 51) variable. Logistic regression and survival analyses were performed. Results: Higher age at RC, analyzed as a continuous or categorical variable, was associated with extravesical disease and pathological upstaging (all p < 0.02). Older patients were less likely to receive postoperative chemotherapy (≤60 yr: 32% vs. >80 yr: 14%, p = 0.008). In both pre- and postoperative multivariate models, higher age at RC as a categorical variable was associated with BCa-specific survival (p < 0.05). Patients >80 yr old had a significantly greater risk of disease recurrence than patients aged ≤60 yr (p < 0.05). Conclusion: Greater patient age at the time of RC for BCa is independently associated with adverse outcomes. Better understanding of factors associated with postoperative outcomes in this growing segment of the population is necessary. Prospective corroboration and further refinement of similar analyses in other large datasets is needed.
AB - Objective: Bladder cancer (BCa) is a disease of older persons, the incidence of which is expected to increase as the population ages. There is controversy, however, regarding the outcomes of radical cystectomy (RC), the gold standard treatment of high-risk BCa, in patients of advanced chronological age. The aim of our study was to assess the impact of patient age on pathological characteristics and recurrence-free and disease-specific survival following RC. Methods: The records of 888 consecutive patients who underwent RC for transitional cell carcinoma (TCC) were reviewed. Age at RC was analyzed both as a continuous (yr) and categorical (≤60 yr old, n = 240; 60.1-70 yr old, n = 331; 70.1-80 yr old, n = 266; >80 yr old, n = 51) variable. Logistic regression and survival analyses were performed. Results: Higher age at RC, analyzed as a continuous or categorical variable, was associated with extravesical disease and pathological upstaging (all p < 0.02). Older patients were less likely to receive postoperative chemotherapy (≤60 yr: 32% vs. >80 yr: 14%, p = 0.008). In both pre- and postoperative multivariate models, higher age at RC as a categorical variable was associated with BCa-specific survival (p < 0.05). Patients >80 yr old had a significantly greater risk of disease recurrence than patients aged ≤60 yr (p < 0.05). Conclusion: Greater patient age at the time of RC for BCa is independently associated with adverse outcomes. Better understanding of factors associated with postoperative outcomes in this growing segment of the population is necessary. Prospective corroboration and further refinement of similar analyses in other large datasets is needed.
KW - Age
KW - Bladder cancer
KW - Cystectomy
KW - Recurrence
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=33846209208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846209208&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2006.11.004
DO - 10.1016/j.eururo.2006.11.004
M3 - Article
C2 - 17113703
AN - SCOPUS:33846209208
SN - 0302-2838
VL - 51
SP - 699
EP - 708
JO - European Urology
JF - European Urology
IS - 3
ER -